VRTX vs. APLS

In the year-to-date period, VRTX achieves a 4.58% return, which is significantly higher than APLS's -47.67% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Vertex Pharmaceuticals Incorporated (VRTX) and Apellis Pharmaceuticals, Inc. (APLS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current VRTX Sharpe Ratio is -0.06, which is higher than the APLS Sharpe Ratio of -1.11. The chart below compares the historical Sharpe Ratios of VRTX and APLS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither VRTX nor APLS has paid dividends to shareholders.

The maximum VRTX drawdown since its inception was -91.77%, which is greater than APLS's maximum drawdown of -82.10%. Use the drawdown chart below to compare losses from any high point for VRTX and APLS. For additional features, visit the drawdowns tool.

Vertex Pharmaceuticals Incorporated (VRTX) and Apellis Pharmaceuticals, Inc. (APLS) have volatilities of 13.18% and 13.40%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Vertex Pharmaceuticals Incorporated and Apellis Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.